Breaking new ground in antibiotic research with neutrons
Dr Luke Clifton, Instrument Scientist at ISIS Neutron and Muon Source, explains how neutrons have emerged as a highly effective tool in the fight against AMR.
Antimicrobial resistance (AMR) has been one of the biggest...
£25m funding for future vaccine development
Three ambitious research projects designed to build our understanding of viruses and how the immune system reacts to different challenges will share £25 million in new funding from UK Research and Innovation (UKRI).
Tackling Infections...
Pain killers made from pine trees instead of crude oil
Common drugs such as paracetamol and ibuprofen can be made from a chemical from pine trees instead of crude oil products.
A team of scientists, from the University of Bath’s Department of Chemistry and Institute...
‘World-first’ immunotherapy drug designed by generative AI
British techbio innovator Etcembly has kickstarted the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI.
The company’s lead therapeutic programme, ETC-101, is the world’s first...
Emerging biotechs jumpstart drug commercialisation via out-licencing – a Deloitte analysis
By Hanno Ronte, life sciences and healthcare partner at Deloitte.
Examining the various go-to-market strategies deployed by emerging biotech companies when launching their first product into Europe reveals how the frequencies of these strategies changed...
Cellular ‘traffic controllers’ caught managing flow of signals from receptors
First time that individual beta-arrestin molecules are directly observed as they control receptor-mediated signals in living cells using advanced microscopy.
New findings could inform the development of better drugs for pain relief,...
Life-saving cancer drug takes a major step closer to patient care
A new drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by biopharmaceutical company Nuvectis Pharma, Inc. (“Nuvectis” or “Company”), can now begin clinical trials as announced by Nuvectis.
The compound,...
Biochemical synthesis breakthrough could unlock new medicines
A mystery about lab synthesis of a natural chemical compound may have been solved – a breakthrough which could unlock new developments in medicine.
Scientists in Scotland and Germany made the discovery, published in the...
Hijacking our cell enzymes to eliminate disease-causing proteins
By studying how enzymes move from one membrane compartment to another inside a cell, scientists at the University of Illinois Chicago have figured out a way to better target cellular proteins, which play a...
New drugs partnership tackles lung disease
Aston University scientists are working with start-up company, Isterian Biotech, part of Cambrian BioPharma, to develop novel drugs to treat fibrotic diseases such as lung disease.
The focus of preclinical-stage biotechnology company Isterian Biotech is...